N/A
Completed N=1,095
An Observational Study to Investigate the Efficacy, Safety, Tolerability and the Effect on Quality of Life of Telmisartan (Micardis) and Telmisartan With HCTZ (Micardis Plus) in Patients With Hypertension
Source: ClinicalTrials.gov NCT00904215 ↗Enrolled (actual)
1,095
Serious AEs
—
Results posted
Aug 2009
Primary outcomePrimary: Change in SBP (Systolic Blood Pressure) — -18 mmHg — p=<0.0001
Summary
An observational study to investigate the efficacy, safety, tolerability and the effect on quality of life of Telmisartan (Micardis) and Telmisartan with HCTZ (Micardis Plus) in patients with hypertension
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in SBP (Systolic Blood Pressure) |
-18 | <0.0001 sig |
| PRIMARY Change in DBP (Diastolic Blood Pressure) |
-10 | <0.0001 sig |
| PRIMARY Change in WHO-QOL (WHO-Quality Of Life) |
2.5 | <0.0001 sig |
| SECONDARY Change in VAS (Visual Analog Scale) |
5.9 | <0.0001 sig |
Eligibility Criteria
Inclusion Criteria
- Ability to provide written/verbal informed consent in accordance with GCP (Good Clinical Practice) and local legislation
- Patients aged 18 ~ under 80
- Hypertension as described below:
- Newly diagnosed patients with hypertension
- Patients with current antihypertensive therapy
Exclusion Criteria
- Female subjects who are breastfeeding, pregnant or who plan to be pregnant during the study
- Known or suspected secondary hypertension(e.g. pheochromocytoma)
- Patients who have been treated with telmisartan prior to the acquisition of informed consent (including verbal informed consent)
Data sourced from ClinicalTrials.gov (NCT00904215). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.